Active, not recruitingPhase 3NCT05925803

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Intervention: Anifrolumab (blinded)(combination_product)
Enrollment: 314 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2023 – 2028

Study locations (30)

Research Site, Scottsdale, Arizona, United States
Research Site, Chula Vista, California, United States
Research Site, Los Angeles, California, United States
Research Site, Orange, California, United States
Research Site, Aurora, Colorado, United States
Research Site, New Haven, Connecticut, United States
Research Site, Washington D.C., District of Columbia, United States
Research Site, Boca Raton, Florida, United States
Research Site, Fort Lauderdale, Florida, United States
Research Site, Gainesville, Florida, United States
Research Site, Jacksonville, Florida, United States
Research Site, Margate, Florida, United States
Research Site, South Miami, Florida, United States
Research Site, Tamarac, Florida, United States
Research Site, Chicago, Illinois, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05925803 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials